Jupiter Topco LLC Buys Shares of 10,826 Natera, Inc. $NTRA

Key Points

• Jupiter Topco LLC acquired 10,826 Natera shares worth approximately $2.94 million during the second quarter. Institutional investors and hedge funds collectively own 99.90% of Natera’s outstanding stock.
• Analysts remain broadly bullish, with an average “Moderate Buy” rating and a consensus price target of $319.38; several firms recently raised or set targets between $340 and $375.
• Natera reported better-than-expected quarterly results, including revenue of $752.75 million—up 37.7% year over year—and an adjusted loss of $0.47 per share versus the expected $0.49 loss. Shares opened at $325.17, near the company’s 12-month high of $343.18.

Jupiter Topco LLC purchased a new position in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 10,826 shares of the medical research company's stock, valued at approximately $2,941,000.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the business. Trust Co. of Vermont acquired a new position in shares of Natera in the second quarter worth $26,000. Reflection Asset Management purchased a new position in shares of Natera in the 4th quarter valued at $29,000. Elevation Wealth Partners LLC acquired a new position in shares of Natera during the second quarter worth about $30,000. Palladiem LLC purchased a new position in Natera in the 4th quarter worth approximately $31,000. Finally, Horizon Investments LLC acquired a new stake in Natera during the 3rd quarter valued at $32,000. Institutional investors and hedge funds own 99.90% of the company's stock.

Analysts Set New Price Targets

A number of equities analysts recently commented on the company. Royal Bank Of Canada lifted their price target on Natera from $275.00 to $350.00 and gave the stock an "outperform" rating in a research note on Friday, August 7th. Canaccord Genuity Group set a $375.00 price target on shares of Natera in a research note on Friday, August 7th. Barclays restated an "overweight" rating and set a $340.00 price objective on shares of Natera in a research note on Friday, August 7th. Wolfe Research initiated coverage on Natera in a research note on Tuesday, June 2nd. They set an "outperform" rating and a $260.00 price target for the company. Finally, Zacks Research raised shares of Natera from a "strong sell" rating to a "hold" rating in a research note on Wednesday, August 12th. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $319.38.

Insiders Place Their Bets

In other Natera news, CEO Steven Leonard Chapman sold 3,580 shares of the company's stock in a transaction dated Tuesday, July 28th. The shares were sold at an average price of $254.07, for a total transaction of $909,570.60. Following the completion of the sale, the chief executive officer directly owned 102,973 shares in the company, valued at $26,162,350.11. This represents a 3.36% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Herm Rosenman sold 16,530 shares of the firm's stock in a transaction that occurred on Wednesday, June 24th. The shares were sold at an average price of $250.00, for a total value of $4,132,500.00. Following the completion of the sale, the director directly owned 4,250 shares in the company, valued at $1,062,500. This trade represents a 79.55% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 62,348 shares of company stock worth $15,870,496 in the last ninety days. 5.05% of the stock is owned by insiders.

Natera Stock Performance

Shares of NTRA stock opened at $325.17 on Thursday. The stock's 50 day simple moving average is $289.96 and its 200 day simple moving average is $236.14. Natera, Inc. has a twelve month low of $157.43 and a twelve month high of $343.18. The company has a market capitalization of $46.87 billion, a price-to-earnings ratio of -239.09 and a beta of 1.54.

Natera (NASDAQ:NTRA - Get Free Report) last announced its earnings results on Thursday, August 6th. The medical research company reported ($0.47) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.49) by $0.02. Natera had a negative return on equity of 11.38% and a negative net margin of 7.11%.The firm had revenue of $752.75 million during the quarter, compared to analysts' expectations of $661.24 million. During the same quarter in the prior year, the business earned ($0.74) earnings per share. The company's revenue was up 37.7% on a year-over-year basis. On average, analysts forecast that Natera, Inc. will post -1.02 EPS for the current fiscal year.

Natera Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source